Table 1

Study and patient characteristics

Study, yearYearsPatients enrolledCancer typeAge (TTD vs PC)TTDPC offered in addition to TTDPCExpected median survival <6 months
Bellmunt, 20092003–2006337UrothelialNRChemotherapyYesPain medication, palliative chemotherapy, supportive care, antibiotics, corticosteroidsYes
Cartei, 1993NR102LungMedian (range): 57 (39–71) vs 56 (41–73)ChemotherapyYesPain medication, radiotherapy, supportive careYes
Ciuleanu, 20092004–2006303PancreaticMedian (range): 58 (27–78) vs 57 (29–80)ChemotherapyYesPain medication, supportive care, appetite stimulatorsYes
De Marinis, 1999a1990–199361LungNRChemotherapyUnclearPain medication, radiotherapy, steroids, progestinsYes
De Marinis, 1999b1990–199363LungNRChemotherapyUnclearPain medication, radiotherapy, steroids, progestinsYes
De Marinis, 1999c1990–199364LungNRChemotherapyUnclearPain medication, radiotherapy, steroids, progestinsYes
Lissoni, 1994aNR50PancreaticMedian (range): 56 (39–71) vs 57 (50–74)ChemotherapyYesPain medication, supportive care, steroids, antiemetics, ansioliticosYes
Lissoni, 1994bNR50Solid tumorsMedian (range): 56 (38–72) vs 58 (42–71)Drug therapyYesSupportive careYes
Ranson, 20001995–1997157LungMedian (range): 65 (37–78) vs 64 (23–82)ChemotherapyYesRadiotherapy, supportive care, corticosteroids, antibiotics, antiemeticsYes
Schmid, 1993a1987–198987EsophagealMedian: 55 vs 53RadiotherapyUnclearIntubation onlyYes
Schmid, 1993b1987–198986EsophagealMedian: 55 vs 53ChemotherapyUnclearIntubation onlyYes
Selawry, 1977aNR150LungMedian: 62 vs 59ChemotherapyUnclearNRYes
Selawry, 1977bNR152LungMedian: 59 vs 59ChemotherapyUnclearNRYes
Xinopoulos, 2008NR73PancreaticMean (range): 66.5 (59–73) vs 66.6 (58–73)ChemotherapyUnclearPlastic biliary endoprosthesis placement as neededYes
  • NR, not reported; PC, palliative care; TTD, treatment targeted at underlying disease.